Abstract
Macrocycles from our Aurora project were screened in a kinase panel and were found to be active on other kinase targets, mainly JAKs, FLT3 and CDKs. Subsequently these compounds became leads in our JAK2 project. Macrocycles with a basic nitrogen in the linker form a salt bridge with Asp86 in CDK2 and Asp698 in FLT3. This residue is conserved in most CDKs resulting in potent pan CDK inhibition. One of the main project objectives was to achieve JAK2 potency with 100-fold selectivity against CDKs. Macrocycles with an ether linker have potent JAK2 activity with the ether oxygen forming a hydrogen bond to Ser936. A hydrogen bond to the equivalent residues of JAK3 and most CDKs cannot be formed resulting in good selectivity for JAK2 over JAK3 and CDKs. Further optimization of the macrocyclic linker and side chain increased JAK2 and FLT3 activity as well as improving DMPK properties. The selective JAK2/FLT3 inhibitor 11 (Pacritinib, SB1518) has successfully finished phase 2 clinical trials for myelofibrosis and lymphoma. Another selective JAK2/FLT3 inhibitor, 33 (SB1578), has entered phase 1 clinical development for the non-oncology indication rheumatoid arthritis.
Similar content being viewed by others
References
Rawlings JS, Rosler KM, Harrison DA (2004) J Cell Sci 117:1281
Bennett M, Stroncek DF (2006) J Transl Med 4:41
Harpur AG, Andres AC, Ziemiecki A, Aston RR, Wilks AF (1992) Oncogene 7:1347
Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P (1997) Blood 90:2535
Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Nat Rev Cancer 7:673
Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdiles MC, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian JJ, Viallard JF, Briere J, Harrison CN, Green AR, Reilly JT (2006) Blood 107:2098
Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC (2006) Blood 108:1377
McLornan D, Percy M, McMullin MF (2006) Ulster Med J 75:112
Apostolidou E, Kantarjian HM, Verstovsek S (2009) Clin Lymphoma Myeloma 9(Suppl 3):S340
Atallah E, Verstovsek S (2009) Expert Rev Anticancer Ther 9:663
Hitoshi Y, Lin N, Payan DG, Markovtsov V (2010) Int J Hematol 91:189
Verstovsek S (2009) Hematol Am Soc Hematol Educ Program 2009:636
Schafer AI (2006) Blood 107:4214
William AD, Lee A, Goh KC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Lee C, Wang H, Williams M, Sun ET, Hu C, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW (2011) J Med Chem 55:169–196
http://www.schrodinger.com. Schrödinger, LLC, New York (2009)
Chang G, Guida WC, Still WC (1989) J Am Chem Soc 111:4379
Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) J Am Chem Soc 118:11225
Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL (2001) J Phys Chem B 105:6474
Hasel WH, Hendrickson TF, Still WC (1988) Tetrahedron Comput Method 1:103
Williams NK, Bamert RS, Patel O, Wang C, Walden PM, Wilks AF, Fantino E, Rossjohn J, Lucet IS (2009) J Mol Biol 387:219
Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE, Walter M, Burns CJ, Treutlein H, Wilks AF, Rossjohn J (2006) Blood 107:176
Boggon TJ, Li Y, Manley PW, Eck MJ (2005) Blood 106:996
Chrencik JE, Patny A, Leung IK, Korniski B, Emmons TL, Hall T, Weinberg RA, Gormley JA, Williams JM, Day JE, Hirsch JL, Kiefer JR, Leone JW, Fischer HD, Sommers CD, Huang HC, Jacobsen EJ, Tenbrink RE, Tomasselli AG, Benson TE (2010) J Mol Biol 400:413
Lawrie AM, Noble ME, Tunnah P, Brown NR, Johnson LN, Endicott JA (1997) Nat Struct Biol 4:796
Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K (2004) Mol Cell 13:169
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) Nucleic Acids Res 28:235
Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A (2003) Nucleic Acids Res 31:3784
Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, Thompson JD (2003) Nucleic Acids Res 31:3497
Jones DT (1999) J Mol Biol 292:195
Pollastri G, Przybylski D, Rost B, Baldi P (2002) Proteins 47:228
Still WC, Tempczyk A, Hawley RC, Hendrickson T (1990) J Am Chem Soc 112:6127
Bostrom J, Norrby PO, Liljefors T (1998) J Comput Aided Mol Des 12:383
Tannor DJ, Marten B, Murphy R, Friesner RA, Sitkoff D, Nicholls A, Honig B, Ringnalda M, Goddard WA (1994) J Am Chem Soc 116:11875
GraphPad. In: GraphPad Software, La Jolla (2009)
Bryant J, Kochanny M, Yuan S, Khim S-K, Buckman B, Arnaiz D, Bomer U, Breim H, Esperling P, Huwe C, Kuhnke J, Schafer M, Wortmann L, Kosemund D, Eckle E, Feldman R, Phillips G (2004) In: Schering Aktiengesellschaft
Burns CJ, Bourke DG, Andrau L, Bu X, Charman SA, Donohue AC, Fantino E, Farrugia M, Feutrill JT, Joffe M, Kling MR, Kurek M, Nero TL, Nguyen T, Palmer JT, Phillips I, Shackleford DM, Sikanyika H, Styles M, Su S, Treutlein H, Zeng J, Wilks AF (2009) Bioorg Med Chem Lett 19:5887
Cao JJ, Hood J, Lohse D, Mak CC, McPherson A, Noronha G, Pathak V, Renick J, Soll R, Zeng B 92007) In: Targegen, Inc
William AD, Lee AC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Tan E, Chen D, Williams M, Sun ET, Goh KC, Ong WC, Goh SK, Hart S, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW (2011) J Med Chem 54:4638
William AD, Lee AC, Poulsen A, Goh KC, Madan B, Hart S, Tan E, Wang H, Nagaraj H, Chen D, Lee CP, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW (2012) J Med Chem 55:2623–2640
Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, William AD, Lee A, Poulsen A, Jayaraman R, Ong KH, Ethirajulu K, Dymock BW, Wood JW (2011) Leukemia 25:1751
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Poulsen, A., William, A., Blanchard, S. et al. Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3). J Comput Aided Mol Des 26, 437–450 (2012). https://doi.org/10.1007/s10822-012-9572-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-012-9572-z